Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues

US9624520B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9624520-B2
Application numberUS-201414279085-A
CountryUS
Kind codeB2
Filing dateMay 15, 2014
Priority dateOct 24, 2008
Publication dateApr 18, 2017
Grant dateApr 18, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed herein is pyrroline-carboxy-lysine (PCL), a pyrrolysine analog, which is a natural, biosynthetically generated amino acid, and methods for biosynthetically generating PCL. Also disclosed herein are proteins, polypeptides and peptides that have PCL incorporated therein and methods for incorporating PCL into such proteins, polypeptides and peptides. Also disclosed herein is the site-specific derivatization of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein. Also disclosed herein is the crosslinking of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein.

First claim

Opening claim text (preview).

We claim: 1. A process for preparing a protein having the structure of Formula (I): R 1 -(AA) n -R 2 wherein: R 1 is H or an amino terminus modification group; R 2 is OH or a carboxy terminus modification group; n is an integer from 1 to 5000; each AA is independently selected from an amino acid residue, a pyrrolysine analogue amino acid residue having the structure of Formula (A-2) and a pyrrolysine analogue amino acid residue having the structure of Formula (B-2); and wherein at least one AA is a pyrrolysine analogue amino acid residue having the structure of Formula (A-2) or Formula (B-2); the process comprising: biosynthetically generate within a cell an amino acid of Formula (VII) or Formula (VIII): wherein the cell comprises a pylC gene, and a pylD gene, and the cell is in contact with a growth medium comprising a precursor, or wherein the cell comprises a pylB gene, a pylC gene and a pylD gene, and the cell is in contact with a growth medium comprising a precursor, incorporating the amino acid of Formula (VII) or Formula (VIII) into the protein within the cell using an orthogonal tRNA (O-tRNA) and an orthogonal aminoacyl tRNA synthetase (O—RS), wherein the O—RS aminoacylates the O-tRNA with the amino acid of Formula (VII) or Formula (VIII) and the O-tRNA recognize at least one selector codon of a mRNA in the cell, and recovering the protein. 2. The process of claim 1 , wherein the cell further comprises a pylS gene and a pylT gene and the amino acid of Formula (VII) or Formula (VIII) is incorporated into the protein within the cell by an aminoacyl tRNA synthetase and a tRNA which recognizes at least one selector codon of a mRNA in the cell, wherein the aminoacyl tRNA synthetase is a gene product of the pylS gene and the tRNA is a gene product of the pylT gene. 3. The process of claim 2 , wherein the selector codon is a TAG amber codon. 4. The process of claim 1 , wherein the precursor is D-ornithine, D-arginine, (2S)-2-amino-6-(2,5-diaminopentanamido)hexanoic acid or (2S)-2-amino-6-((R)-2,5-diaminopentanamido)hexanoic acid. 5. The process of claim 1 , wherein the cell is a prokaryotic cell or a eukaryotic cell. 6. The process of claim 5 , wherein the cell is an Escherichia coli cell, a mammalian cell, a yeast cell or an insect cell. 7. The process of claim 6 , wherein the mammalian cell is a CHO cell, a HeLa cell or a HEK293F cell and the insect cell is a sf9 cell.

Assignees

Inventors

Classifications

  • with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title

  • C12P21/00Primary

    Preparation of peptides or proteins (single cell protein C12N1/00) · CPC title

  • Sulfur atoms · CPC title

  • containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu · CPC title

  • C07K2/00Primary

    Peptides of undefined number of amino acids; Derivatives thereof · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9624520B2 cover?
Disclosed herein is pyrroline-carboxy-lysine (PCL), a pyrrolysine analog, which is a natural, biosynthetically generated amino acid, and methods for biosynthetically generating PCL. Also disclosed herein are proteins, polypeptides and peptides that have PCL incorporated therein and methods for incorporating PCL into such proteins, polypeptides and peptides. Also disclosed herein is the site-spe…
Who is the assignee on this patent?
Geierstanger Bernhard, Ou Weijia, Cellitti Susan E, and 6 more
What technology area does this patent fall under?
Primary CPC classification C12P21/00. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).